These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6834012)

  • 21. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Virus Res; 2004 Jul; 103(1-2):139-45. PubMed ID: 15163502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibody determination following influenza vaccination].
    Wegmann A
    Ther Umsch; 1972 Dec; 29(12):747-9. PubMed ID: 4639117
    [No Abstract]   [Full Text] [Related]  

  • 23. Influenza virus vaccination of patients with chronic lung disease.
    Gorse GJ; Otto EE; Daughaday CC; Newman FK; Eickhoff CS; Powers DC; Lusk RH
    Chest; 1997 Nov; 112(5):1221-33. PubMed ID: 9367461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ineffectiveness of the 2014-2015 H3N2 influenza vaccine.
    Mandelboim M; Glatman-Freedman A; Drori Y; Sherbany H; Pando R; Sefty H; Zadka H; Shohat T; Keller N; Mendelson E
    Oncotarget; 2016 Jan; 7(2):1185-92. PubMed ID: 26716420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Virologic-immunological basis and current status of influenza vaccination in the Federal Republic of Germany].
    Kuwert EK
    Med Welt; 1977 Oct; 28(40):1599-1610. PubMed ID: 927117
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.
    Elkayam O
    Clin Dev Immunol; 2006; 13(2-4):349-51. PubMed ID: 17162376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.
    Tregnaghi MW; Stamboulian D; Vanadía PC; Tregnaghi JP; Calvari M; Fragapane E; Casula D; Pellegrini M; Groth N
    Viral Immunol; 2012 Jun; 25(3):216-25. PubMed ID: 22691101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza vaccination in renal transplant recipients.
    Kumar SS; Ventura AK; VanderWerf B
    JAMA; 1978 Feb; 239(9):840-2. PubMed ID: 342736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
    Burt D; Mallett C; Plante M; Zimmermann J; Torossian K; Fries L
    Expert Rev Vaccines; 2011 Mar; 10(3):365-75. PubMed ID: 21434804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity and serologic response to trivalent inactivated A/Texas, A/USSR and B/Hong Kong whole-virus influenza vaccine in human volunteers.
    Lavergne B; Frappier-Davignon L; Chagnon A; Burr-Paxton M; Quevillon M; Pavilanis V; Beaulnes A
    Can J Public Health; 1980; 71(1):25-31. PubMed ID: 6991090
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of influenza vaccination.
    Hannoun C; Megas F; Piercy J
    Virus Res; 2004 Jul; 103(1-2):133-8. PubMed ID: 15163501
    [No Abstract]   [Full Text] [Related]  

  • 32. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.
    Andrews SF; Kaur K; Pauli NT; Huang M; Huang Y; Wilson PC
    J Virol; 2015 Mar; 89(6):3308-17. PubMed ID: 25589639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization against human and swine-like influenza A: serological response to two inactivated vaccines of different formulation.
    Cuneo-Crovari P; Giacometti G; Gasparini R; Fontana G
    Boll Ist Sieroter Milan; 1976; 55(5):371-8. PubMed ID: 1016590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial of a subunit influenza vaccine.
    Pyrhönen S; Suni J; Romo M
    Scand J Infect Dis; 1981; 13(2):95-9. PubMed ID: 7031855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation of antineuraminidase antibodies and antihemagglutinins in influenza and following administration of live influenza vaccine].
    Nekliudova LI; Fedorova IuB; Orlova NG
    Vopr Virusol; 1974; (2):173-6. PubMed ID: 4446555
    [No Abstract]   [Full Text] [Related]  

  • 36. Influenzal vaccine response in systemic lupus erythematosus.
    Brodman R; Gilfillan R; Glass D; Schur PH
    Ann Intern Med; 1978 Jun; 88(6):735-40. PubMed ID: 307353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative evaluation of influenza antibody titers in enzyme immunoassays and other serologic reactions following preventive vaccination and in influenza patients].
    Schmidt J; Adamczyk B; Gruhn I; Oehring H; Süss J; Vogt KH; Brunnemann H; Michaelis I; Schmidt S; Kittlick M
    Z Gesamte Hyg; 1984 Aug; 30(8):436-41. PubMed ID: 6385499
    [No Abstract]   [Full Text] [Related]  

  • 38. Influenza virus immunization. Antibody response and adverse effects in children with renal disease.
    Sheth KJ; Freeman ME; Eisenberg C; Sedmak GV
    JAMA; 1978 Jun; 239(24):2559-61. PubMed ID: 660787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus.
    Louie JS; Nies KM; Shoji KT; Fraback RC; Abrass C; Border W; Cherry JD; Imagawa D
    Ann Intern Med; 1978 Jun; 88(6):790-2. PubMed ID: 307356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reactogenic properties and the immunological activity of an absorbed influenza chemical vaccine].
    Rudenko LG; Ishkil'din MI; Esorov PA; Ranevskiĭ VD; Zoshchenkova PIa
    Tr Inst Im Pastera; 1976; 47():160-3. PubMed ID: 802568
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.